Innate Immunotherapeutics Share Price has Bombed 91.25%

What happened to cause such a large share price drop for ASX:IIL?

Innate Immunotherapies [ASX:IIL], a medical biotech company, has seen its share price hammered today. The company has been in a trading halt since Friday afternoon after it received results from one of their clinical trials. Innate had been working on a drug to treat multiple sclerosis. Today they announced that the MIS416 drug had no effect in treating patients. The news is dire for both the company and investors.

Innate invited shareholders to participate in an investor conference call earlier this morning. Though it looks to have done little to ease the offloading of shares.

What now for Innate?

Simon Wilkinson, CEO, states the results were ‘a shock’ and did not align with previous indications. He believes the results are as distressing for investors as they are MS sufferers, with few treatments for the illness. Innate will now be looking into alternative uses for the drug moving forward.

The short term future for the company will be rough, having just recently publicised their full year earnings last week. In it they stated, ‘The outlook for the Group relies principally on the results of this study (MIS416)’. Their share price shows the market felt the same way, and now they’re being punished for it.


Ryan Clarkson-Ledward,
Junior Analyst, Money Morning

PS: If you want to avoid more price shocks, you need to read Vern Gowdie’s report, ‘Five Fatal Stocks You Must Sell Now’.

Vern believes we’re in the ‘bubble of all bubbles’, and he’s got the research to back it up.

To learn about these five lethal shares and how you can avoid losing your precious wealth, read Vern’s report right now, here.

Ryan Clarkson-Ledward is an Editor at Money Morning.

Ryan holds degrees in both communication and international business. He helps bring Money Morning readers the latest market updates, both locally and abroad. Ryan tackles all the issues investors need to know about that the mainstream media neglects.

Ryan is also the Editor of Australian Small-Cap Investigator, a stock tipping newsletter that hunts down promising small-cap stocks by dissecting the latest events affecting the world.

To find out more about the publications Ryan works on and how you can subscribe, please click on the corresponding link here:

Money Morning Australia